News Pfizer targets $2.5bn more in cost savings Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.
News BMS, Pfizer take DTC route for blood thinner Eliquis BMS, Pfizer launch direct-to-patient sales for anticoagulant Eliquis, as a report cites conflict-of-interest concerns about the emerging DTC channel.
News BMS files legal challenge to HHS' 340B rebate decision Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.
News Pfizer's COVID boom goes on, as it eyes $22bn in Paxlovid sa... Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirna
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
